[go: up one dir, main page]

MX2011012666A - Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares. - Google Patents

Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares.

Info

Publication number
MX2011012666A
MX2011012666A MX2011012666A MX2011012666A MX2011012666A MX 2011012666 A MX2011012666 A MX 2011012666A MX 2011012666 A MX2011012666 A MX 2011012666A MX 2011012666 A MX2011012666 A MX 2011012666A MX 2011012666 A MX2011012666 A MX 2011012666A
Authority
MX
Mexico
Prior art keywords
cardiovascular
antibodies
binding fragments
related uses
cardiovascular related
Prior art date
Application number
MX2011012666A
Other languages
English (en)
Inventor
Patrick J Scannon
Alan M Solinger
Jeffrey D Feldstein
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Publication of MX2011012666A publication Critical patent/MX2011012666A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen métodos para la reducción, prevención o tratamiento de eventos cardiovasculares y/o enfermedades cardiovasculares, incluyendo enfermedad cardiovascular aguda o enfermedad cardiovascular crónica utilizando moléculas de unión anti-IL-1ß (por ejemplo, anticuerpos de unión IL-1ß y sus fragmentos) . La presente descripción también se refiere a métodos para la prevención o tratamiento de eventos cardiovasculares y/o enfermedades cardiovasculares, incluyendo a través de la reducción de un evento o enfermedad cardiovascular.
MX2011012666A 2009-05-29 2010-05-28 Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares. MX2011012666A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18267909P 2009-05-29 2009-05-29
US25257109P 2009-10-16 2009-10-16
US31300110P 2010-03-11 2010-03-11
PCT/US2010/036761 WO2010138939A1 (en) 2009-05-29 2010-05-28 CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF

Publications (1)

Publication Number Publication Date
MX2011012666A true MX2011012666A (es) 2011-12-16

Family

ID=43223130

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012666A MX2011012666A (es) 2009-05-29 2010-05-28 Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares.

Country Status (15)

Country Link
US (3) US20100316651A1 (es)
EP (1) EP2435073A4 (es)
JP (2) JP5763625B2 (es)
KR (1) KR20120061041A (es)
CN (2) CN107243077A (es)
AU (1) AU2010253924B2 (es)
BR (1) BRPI1011228A2 (es)
CA (1) CA2763161A1 (es)
EA (1) EA201101643A1 (es)
HK (1) HK1245111A1 (es)
IL (1) IL216660A0 (es)
MX (1) MX2011012666A (es)
NZ (1) NZ597024A (es)
SG (3) SG176265A1 (es)
WO (1) WO2010138939A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2623039C2 (ru) * 2011-04-01 2017-06-21 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта
AU2012316083A1 (en) * 2011-09-30 2014-04-17 Novartis Ag Use of IL-1 beta binding antibodies
DK2623604T3 (da) * 2012-02-02 2015-06-01 Baylor College Medicine Adenovirusbaseret biologisk afgivelses- og ekspressionssystem til anvendelse ved behandling af osteoartrose
CN103588878A (zh) * 2012-08-15 2014-02-19 江苏泰康生物医药有限公司 一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
AU2013327501B2 (en) * 2012-10-04 2018-08-09 Xbiotech Inc. Treating vascular disease and complications thereof
CA2891556A1 (en) * 2012-11-16 2014-05-22 Novartis Ag Use of il-1 beta binding antibodies for treating peripheral arterial disease
US10000557B2 (en) * 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
CN103059136A (zh) * 2012-12-24 2013-04-24 浙江大学 抗中华鳖IL-1β多克隆抗体的制备及在检测中的应用
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
JP2022531328A (ja) * 2019-05-03 2022-07-06 ユニバーシティ・オブ・チューリッヒ 脳虚血再灌流傷害の治療
US20220275079A1 (en) * 2020-11-20 2022-09-01 The General Hospital Corporation Clonal Hematopoiesis and Risk of Chronic Liver Disease
GB202400340D0 (en) 2024-01-10 2024-02-21 Wotherspoon Hugh Robert IL-1B binding antibody

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
AR016551A1 (es) * 1997-07-30 2001-07-25 Smithkline Beecham Corp Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US7860583B2 (en) * 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
EP1379197A4 (en) * 2001-03-23 2009-06-03 Durect Corp DISPOSAL OF MEDICINAL PRODUCTS OF DELAYED RELEASE DEVICES IMPLANTED IN MYOKARD TISSUE OR PER ICARDROOM
US20040106954A1 (en) * 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US20060171948A1 (en) * 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein
WO2006084145A2 (en) * 2005-02-02 2006-08-10 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to reduce c-reactive protein
CA2605024C (en) 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
PT1899378E (pt) * 2005-06-21 2010-01-26 Xoma Technology Ltd Anticorpos de ligação de il-1β e os seus fragmentos
EP1940880A2 (en) * 2005-10-14 2008-07-09 Novo Nordisk A/S Treating diabetes using inhibitors of il-1
JP4524275B2 (ja) * 2006-09-01 2010-08-11 日本ポリプロ株式会社 ビニル基および極性基含有プロピレン系共重合体及びそれを用いる重合体の製造方法。
US7695718B2 (en) * 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases

Also Published As

Publication number Publication date
WO2010138939A1 (en) 2010-12-02
HK1245111A1 (zh) 2018-08-24
EA201101643A1 (ru) 2012-12-28
US10611832B2 (en) 2020-04-07
IL216660A0 (en) 2012-02-29
SG2014014534A (en) 2014-07-30
JP2012528796A (ja) 2012-11-15
US20210009679A1 (en) 2021-01-14
NZ597024A (en) 2014-01-31
US20100316651A1 (en) 2010-12-16
CN107243077A (zh) 2017-10-13
CN102573893A (zh) 2012-07-11
KR20120061041A (ko) 2012-06-12
EP2435073A4 (en) 2013-03-27
AU2010253924A1 (en) 2012-01-19
SG176265A1 (en) 2012-01-30
BRPI1011228A2 (pt) 2019-09-24
EP2435073A1 (en) 2012-04-04
AU2010253924B2 (en) 2015-01-22
SG10201500180RA (en) 2015-03-30
JP2015120704A (ja) 2015-07-02
US20180155420A1 (en) 2018-06-07
JP5763625B2 (ja) 2015-08-12
CA2763161A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
MX2011012666A (es) Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares.
MX2010006823A (es) Metodos para el tratamiento de la gota.
NZ593314A (en) Dual variable domain immunoglobulins and uses thereof
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
WO2010066803A3 (en) Human antibodies against human tissue factor
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12012500774A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12012500815A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012004415A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2012001262A (es) Inmunoglobulinas de dominio variable doble y usos de las misma.
MX2011011669A (es) Inmunoglobulinas de dominio variable dual y usos de las misma.
WO2010096418A3 (en) Antibody molecules having specificity for human ox40
WO2012062925A3 (en) Compounds and methods for treating pain
PH12013500355A1 (en) Engineered anti-tslp antibody
MY195289A (en) Anti IL-36R Antibodies
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
MX2009013990A (es) Metodos para tratar enfermedades y trastornos mediados por serotonina.
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
UA106890C2 (uk) Гуманізоване антитіло до cdcp1
WO2012007880A3 (en) Modified single domain antigen binding molecules and uses thereof
MX2009008410A (es) Elementos de aglutinacion para moleculas de ige.
WO2008027739A3 (en) Antibodies to ntb-a

Legal Events

Date Code Title Description
FG Grant or registration